Recent advancements in oncology have transformed the landscape of HCT donor selection. A groundbreaking study by Mehta RS et al., published in J Hematol Oncol, utilized a double machine-learning framework to separate the risks of relapse from non-relapse mortality (NRM). By evaluating over 8,500 patients, the researchers successfully decoupled these competing outcomes. They discovered that while disease biology drives relapse, physiological reserve governs the risk of non-relapse mortality. Consequently, this provides clinicians with a more nuanced understanding of patient-specific risks.

Specifically, the study identifies a significant "vascular penalty" for certain transplant candidates. Patients with cardiovascular or cerebrovascular comorbidities faced a much higher mortality risk when undergoing haploidentical transplants. These comorbidities acted as selective amplifiers, essentially doubling the mortality risk in the modeled cohorts. Therefore, assessing vascular health is now a vital component of the transplant evaluation process to prevent avoidable toxicity.

Improved Outcomes via HCT Donor Selection Nomograms

Moreover, the research team developed a three-factor nomogram to guide practitioners. This tool incorporates recipient age, vascular comorbidity status, and B-leader matching to identify an "Optimized Haploidentical" phenotype. While matched unrelated donors (MUD) consistently maximized predicted disease-free survival, the model revealed a unique zone of equivalence. For older patients aged 60 and above, B-leader matched haploidentical donors showed outcomes nearly identical to matched related donors.

Additionally, the investigators noted that B-leader mismatching generally favors related donors across all age groups. This insight helps clinicians refine their strategies for HCT donor selection, particularly when a matched related donor is unavailable. By utilizing these individualized survival estimates, transplant teams can better balance the potent graft-versus-tumor effects of haploidentical cells with the patient's physiological limitations. In addition, these findings underscore the importance of precision medicine in modern hematology.

Frequently Asked Questions

What is the vascular penalty in haploidentical transplants?

The vascular penalty refers to the increased mortality risk observed in haploidentical transplant recipients with cardiovascular or cerebrovascular comorbidities. The study found that these conditions can double the risk of non-relapse mortality.

Can haploidentical donors be as effective as related donors for older patients?

Yes, the study identified a hypothesis-generating zone of equivalence. In patients aged 60 years and older, B-leader matched haploidentical donors provided disease-free survival rates nearly equivalent to matched related donors.

How does the new nomogram aid in donor choice?

The 3-factor nomogram uses recipient age, vascular health, and B-leader status to identify the "Optimized Haploidentical" phenotype. This helps clinicians choose the donor type that minimizes toxicity while maintaining efficacy.

Disclaimer: This content is for informational and educational purposes only. It should not replace professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Mehta RS et al. Uncoupling toxicity from efficacy in donor selection for allogeneic hematopoietic cell transplantation: a retrospective cohort study using double machine learning. J Hematol Oncol. 2026 Apr 20. doi: undefined. PMID: 42010448.

Blaise D et al. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica. 2014 Nov;99(11):1762-8.